Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration.

Acta Neuropathol 2009 Nov 13;118(5):647-58. Epub 2009 Oct 13.

Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.

In the present study, we have correlated plasma TDP-43 levels, as measured by ELISA, with the presence of TDP-43 pathological changes in the brains of 28 patients with frontotemporal lobar degeneration (FTLD) (14 with FTLD-TDP and 14 with FTLD-tau) and 24 patients with pathologically confirmed AD (8 with, and 16 without, TDP-43 pathological changes). Western blotting revealed full-length TDP-43, including a phosphorylated form, and a phosphorylated C-terminal fragment, in all samples examined. Both ELISA and immunohistochemistry were performed using phospho-dependent and phospho-independent TDP-43 antibodies for detection of phosphorylated and total TDP-43, respectively. Over all 52 cases, plasma levels of TDP-43, and scores of brain TDP-43 pathology, determined using TDP-43 phospho-dependent antibody correlated with the equivalent measure determined using the TDP phospho-independent antibody. In FTLD, but not AD, TDP-43 plasma levels correlated significantly with the pathology score when using the TDP-43 phospho-dependent antibody, but a similar correlation was not seen in either FTLD or AD using the TDP-43 phospho-independent antibody. With the TDP-43 phospho-independent antibody, there were no significant differences in median plasma TDP-43 levels between FTLD, or AD, patients with or without TDP-43 pathology. Using TDP-43 phospho-dependent antibody, median plasma TDP-43 levels were greater in patients with, than in those without, TDP-43 pathology for FTLD patients, though not significantly so, but not for AD patients. Present assays for TDP-43 do not differentiate between FTLD, or AD, patients with or without TDP-43 pathological changes in their brains. However, the levels of phosphorylated TDP-43 in plasma do correlate with the extent of TDP-43 brain pathology in FTLD, and therefore might be a useful surrogate marker for tracking changes in TDP-43 brain pathology during the course of this disease.

Download full-text PDF

Source
http://link.springer.com/10.1007/s00401-009-0594-0
Publisher Site
http://dx.doi.org/10.1007/s00401-009-0594-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809136PMC
November 2009
19 Reads

Publication Analysis

Top Keywords

tdp-43
23
tdp-43 phospho-dependent
12
plasma tdp-43
12
phospho-dependent antibody
12
tdp-43 pathology
12
patients tdp-43
12
phospho-independent antibody
12
pathological changes
12
ftld patients
12
tdp-43 pathological
12
brain pathology
12
tdp-43 levels
12
tdp-43 phospho-independent
8
pathology ftld
8
median plasma
8
changes brains
8
lobar degeneration
8
tdp-43 brain
8
tdp-43 plasma
8
ftld tdp-43
8

Altmetric Statistics

References

(Supplied by CrossRef)

C Amador-Ortiz et al.
Ann Neurol 2007

T Arai et al.
Biochem Biophys Res Commun 2006

T Arai et al.
Acta Neuropathol 2009

M Baker et al.
Nature 2006

BF Boeve et al.
Brain 2006

M Cruts et al.
Nature 2006

Y Davidson et al.
Acta Neuropathol 2007

DW Dickson et al.
Acta Neuropathol 2007

P Foulds et al.
Acta Neuropathol 2008

H Fujishiro et al.
Acta Neuropathol 2009

M Hasegawa et al.
Ann Neurol 2008

Similar Publications